Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
出版年份 2019 全文链接
标题
Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
作者
关键词
-
出版物
JOURNAL OF CLINICAL LABORATORY ANALYSIS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-07-08
DOI
10.1002/jcla.22964
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer
- (2019) Wei Guo et al. Thoracic Cancer
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
- (2018) Carlo Putzu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria
- (2018) Hongyuan Fu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
- (2018) Katsutoshi Sekine et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer
- (2018) Takayuki Takeda et al. Thoracic Cancer
- Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
- (2018) Qiaoyun Tan et al. Thoracic Cancer
- Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
- (2018) Won Jin Ho et al. Journal for ImmunoTherapy of Cancer
- A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma
- (2017) Lu Wang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Systemic immune-inflammation index for predicting prognosis of colorectal cancer
- (2017) Jian-Hui Chen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: The Fujian prospective investigation of cancer (FIESTA) study
- (2017) Feng Peng et al. Journal of Cancer
- Tumour microenvironment factors shaping the cancer metabolism landscape
- (2016) Dimitrios Anastasiou BRITISH JOURNAL OF CANCER
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer
- (2016) ZHEN-YU ZOU et al. Oncology Letters
- Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis
- (2015) Hariruk Yodying et al. ANNALS OF SURGICAL ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis
- (2015) Jian-Jun Yang WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) A. J. Templeton et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma
- (2014) Ji-Feng Feng et al. World Journal of Surgical Oncology
- Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
- (2013) M Stotz et al. BRITISH JOURNAL OF CANCER
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More